Natera, Inc. (NTRA): Price and Financial Metrics


Natera, Inc. (NTRA): $44.35

0.53 (+1.21%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

NTRA POWR Grades

  • NTRA scores best on the Growth dimension, with a Growth rank ahead of 57.2% of US stocks.
  • NTRA's strongest trending metric is Growth; it's been moving up over the last 177 days.
  • NTRA ranks lowest in Momentum; there it ranks in the 4th percentile.

NTRA Stock Summary

  • With a price/sales ratio of 5.7, NATERA INC has a higher such ratio than 81.28% of stocks in our set.
  • Over the past twelve months, NTRA has reported earnings growth of 87.95%, putting it ahead of 83.46% of US stocks in our set.
  • The volatility of NATERA INC's share price is greater than that of 82.5% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to NATERA INC, a group of peers worth examining would be LNSR, OCX, NSTG, VRCA, and ONDS.
  • NTRA's SEC filings can be seen here. And to visit NATERA INC's official web site, go to www.natera.com.

NTRA Valuation Summary

  • In comparison to the median Healthcare stock, NTRA's price/sales ratio is 24.73% higher, now standing at 5.8.
  • NTRA's price/sales ratio has moved down 1.1 over the prior 88 months.

Below are key valuation metrics over time for NTRA.

Stock Date P/S P/B P/E EV/EBIT
NTRA 2022-09-23 5.8 9.5 -7.4 -8.0
NTRA 2022-09-22 6.2 10.1 -7.8 -8.4
NTRA 2022-09-21 6.5 10.6 -8.2 -8.8
NTRA 2022-09-20 6.6 10.7 -8.2 -8.9
NTRA 2022-09-19 6.6 10.7 -8.2 -8.9
NTRA 2022-09-16 6.5 10.6 -8.2 -8.8

NTRA Growth Metrics

    Its year over year price growth rate is now at -64.57%.
  • Its 5 year cash and equivalents growth rate is now at 193.02%.
  • Its year over year net cashflow from operations growth rate is now at -78.88%.
Over the past 15 months, NTRA's revenue has gone up $274,168,000.

The table below shows NTRA's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 723.477 -437.923 -575.583
2022-03-31 667.303 -397.637 -546.458
2021-12-31 625.486 -335.236 -471.716
2021-09-30 564.836 -309.802 -407.564
2021-06-30 504.863 -251.871 -314.614
2021-03-31 449.309 -222.288 -258.225

NTRA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • NTRA has a Quality Grade of D, ranking ahead of 16.91% of graded US stocks.
  • NTRA's asset turnover comes in at 0.553 -- ranking 46th of 81 Healthcare stocks.
  • CHE, USPH, and VCYT are the stocks whose asset turnover ratios are most correlated with NTRA.

The table below shows NTRA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.553 0.496 -0.316
2021-03-31 0.510 0.498 -0.272
2020-12-31 0.490 0.479 -0.286
2020-09-30 0.509 0.480 -0.277
2020-06-30 0.609 0.472 -0.279
2020-03-31 0.692 0.462 -0.273

NTRA Price Target

For more insight on analysts targets of NTRA, see our NTRA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $150.11 Average Broker Recommendation 1.35 (Strong Buy)

NTRA Stock Price Chart Interactive Chart >

Price chart for NTRA

NTRA Price/Volume Stats

Current price $44.35 52-week high $121.05
Prev. close $43.82 52-week low $26.10
Day low $43.04 Volume 121,069
Day high $44.66 Avg. volume 1,749,663
50-day MA $49.29 Dividend yield N/A
200-day MA $50.65 Market Cap 4.30B

Natera, Inc. (NTRA) Company Bio


Natera Inc. is a genetic testing company that develops and commercializes non-invasive methods for analyzing DNA. The company was founded in 2003 and is based in San Carlos, California.


NTRA Latest News Stream


Event/Time News Detail
Loading, please wait...

NTRA Latest Social Stream


Loading social stream, please wait...

View Full NTRA Social Stream

Latest NTRA News From Around the Web

Below are the latest news stories about NATERA INC that investors may wish to consider to help them evaluate NTRA as an investment opportunity.

Natera Announces 2025 ESG Goals with Publication of 2021 Report

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the publication of its 2021 Environmental, Social and Governance (ESG) report detailing the company's commitment to environmental sustainability, social equity and improved access to health care. The report, which can be found here, includes the company's 2025 ESG Goals.

Yahoo | September 29, 2022

Natera Presents New Colorectal and Breast Cancer Data at ESMO 2022, Highlighting Signatera's Ability to Inform Treatment Decisions in the Adjuvant and Neoadjuvant Settings

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera™, at the 2022 European Society for Medical Oncology (ESMO) World Congress, taking place September 9-13 in Paris, France.

Yahoo | September 12, 2022

Natera to Participate in Upcoming Investor Conferences

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that Steve Chapman, chief executive officer, and Mike Brophy, chief financial officer, will be presenting at the following upcoming investor conferences:

Yahoo | September 6, 2022

Natera Earns Great Place to Work Certification™ for Second Consecutive Year

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, is proud to be certified by Great Place to Work® for the second consecutive year. The certification is based entirely on how current employees rate their experience working at Natera in an independently administered, anonymous survey.

Yahoo | August 25, 2022

Natera Announces Enrollment Completion for RenaCARE Study

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced full enrollment for the RenaCARE (Renasight Clinical Application, Review and Evaluation) study, a real world, prospective, multi-center clinical study to assess the clinical utility of Natera's Renasight™ genetic testing panel, which analyzes more than 380 genes related to kidney disease. Enrollment in the study was completed early as a result of statistically meaningful interim data analysis. The study includ

Yahoo | August 11, 2022

Read More 'NTRA' Stories Here

NTRA Price Returns

1-mo -6.93%
3-mo 14.33%
6-mo 4.87%
1-year -60.54%
3-year 25.04%
5-year 221.84%
YTD -52.51%
2021 -6.16%
2020 195.40%
2019 141.33%
2018 55.28%
2017 -23.23%

Continue Researching NTRA

Here are a few links from around the web to help you further your research on Natera Inc's stock as an investment opportunity:

Natera Inc (NTRA) Stock Price | Nasdaq
Natera Inc (NTRA) Stock Quote, History and News - Yahoo Finance
Natera Inc (NTRA) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6048 seconds.